MaxCyte, Inc. (MXCT)
| Market Cap | 141.40M -3.9% |
| Revenue (ttm) | 31.05M -13.2% |
| Net Income | -35.64M |
| EPS | -0.33 |
| Shares Out | 107.12M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,003,418 |
| Open | 1.390 |
| Previous Close | 1.390 |
| Day's Range | 1.270 - 1.407 |
| 52-Week Range | 0.643 - 1.865 |
| Beta | 1.49 |
| Analysts | Strong Buy |
| Price Target | 4.11 (+211.36%) |
| Earnings Date | Aug 12, 2026 |
About MXCT
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engi... [Read more]
Financial Performance
In 2025, MaxCyte's revenue was $33.03 million, a decrease of -14.50% compared to the previous year's $38.63 million. Losses were -$44.63 million, 8.71% more than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for MXCT stock is "Strong Buy." The 12-month stock price target is $4.11, which is an increase of 211.36% from the latest price.
News
MaxCyte Earnings Call Transcript: Q2 2026
Q2 2026 revenue stabilized and exceeded expectations despite prior headwinds, with sequential growth driven by instrument placements and a major Genentech partnership. Operating expenses fell 25% year-over-year, and 2026 guidance was reiterated, supported by a strong cash position and diversified revenue streams.
MaxCyte Earnings release: Q2 2026
MaxCyte released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
MaxCyte Quarterly report: Q2 2026
MaxCyte has published its Q2 2026 quarterly earnings report on August 12, 2026.
MaxCyte Reports Second Quarter 2026 Financial Results
Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue Reiterates Full Year 2026 Guidance Repurcha...
MaxCyte Slides: Corporate presentation
MaxCyte has posted slides in relation to its latest quarterly earnings report, which was published on August 12, 2026.
MaxCyte enters technology license partnership with Genentech
MaxCyte (MXCT) announced that it has entered into a technology license partnership with Genentech, a member of Roche (RHHBY), to support the development of cell therapy programs. The license provides…
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
ROCKVILLE, Md., July 21, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and c...
MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026
ROCKVILLE, Md., July 15, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, developm...
VectorBuilder Partners With MaxCyte® to Advance Clinical-Grade Cell Engineering
ROCKVILLE, Md. & CHICAGO--(BUSINESS WIRE)-- #BioTechNews--VectorBuilder, a global leader in gene delivery technologies and CDMO services, and MaxCyte, a leading, cell-engineering company providing ena...
MaxCyte reports Q1 EPS (4c), consensus (9c)
Reports Q1 revenue $9.65M, consensus $7.3M. “We are pleased with our performance in the first quarter, and remain confident in our full year guidance,” said Maher Masoud, President and CEO…
MaxCyte backs FY26 revenue view $30M-$32M, consensus $30.83M
The company said, “MaxCyte (MXCT) expects to end 2026 with at least $136 million in total cash, cash equivalents and investments, which does not include capital to be used for…
MaxCyte Earnings Call Transcript: Q1 2026
Q1 2026 revenue met expectations but declined year-over-year due to SPL program turnover and inventory management. Guidance for 2026 is reiterated, with revenue weighted to the second half and a $10 million share repurchase program authorized.
MaxCyte Earnings release: Q1 2026
MaxCyte released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
MaxCyte Quarterly report: Q1 2026
MaxCyte has published its Q1 2026 quarterly earnings report on May 12, 2026.
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
First quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related revenue Reiterates 2026 revenue guidance of $30-32 million; with Core r...
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026
ROCKVILLE, Md., April 29, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, develop...
MaxCyte Proxy statement: Proxy filing
MaxCyte filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
MaxCyte Proxy statement: Proxy filing
MaxCyte filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ROCKVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, developme...
MaxCyte price target lowered to $5 from $7 at Craig-Hallum
Craig-Hallum lowered the firm’s price target on MaxCyte (MXCT) to $5 from $7 and keeps a Buy rating on the shares. The firm notes the company reported an ostensibly weak…
MaxCyte Earnings Call Transcript: Q4 2025
2025 saw revenue decline 15% year-over-year amid SPL program exits and inventory headwinds, but new product launches, cost restructuring, and a strong balance sheet position the company for growth. 2026 guidance anticipates $30–32 million in revenue, with a back-half weighted recovery and material contributions from SeQure Dx and SPL milestones.
MaxCyte Annual report: Q4 2025
MaxCyte has published its Q4 2025 annual report on March 24, 2026.
MaxCyte Earnings release: Q4 2025
MaxCyte released its Q4 2025 earnings on March 24, 2026, summarizing the period's financial results.
MaxCyte sees FY26 revenue $30M-$32M, consensus $38.41M
The company said, “MaxCyte (MXCT) expects to end 2026 with at least $136 million in total cash, cash equivalents and investments.”
MaxCyte reports Q4 EPS (9c), consensus (8c)
Reports Q4 revenue $7.3M, consensus $9.16M. “Our 2025 revenues were impacted by headwinds from select SPL customers, including a 15% reduction in purchases and leases from our largest customer, which…